AR056615A1 - Un metodo de tratamiento de trastornos de la conducta - Google Patents
Un metodo de tratamiento de trastornos de la conductaInfo
- Publication number
- AR056615A1 AR056615A1 ARP030104811A ARP030104811A AR056615A1 AR 056615 A1 AR056615 A1 AR 056615A1 AR P030104811 A ARP030104811 A AR P030104811A AR P030104811 A ARP030104811 A AR P030104811A AR 056615 A1 AR056615 A1 AR 056615A1
- Authority
- AR
- Argentina
- Prior art keywords
- treatment
- behavior disorders
- disorders
- dimethoxystyryl
- methylxanthine
- Prior art date
Links
- 208000020016 psychiatric disease Diseases 0.000 title 1
- 208000006096 Attention Deficit Disorder with Hyperactivity Diseases 0.000 abstract 1
- 208000036864 Attention deficit/hyperactivity disease Diseases 0.000 abstract 1
- 208000015802 attention deficit-hyperactivity disease Diseases 0.000 abstract 1
- 230000003542 behavioural effect Effects 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- IQVRBWUUXZMOPW-PKNBQFBNSA-N istradefylline Chemical compound CN1C=2C(=O)N(CC)C(=O)N(CC)C=2N=C1\C=C\C1=CC=C(OC)C(OC)=C1 IQVRBWUUXZMOPW-PKNBQFBNSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Psychology (AREA)
- Anesthesiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Método de tratamiento de trastornos de la conducta tales como trastorno de hiperactividad con déficit de la atencion, que comprende la administracion de una cantidad eficaz de (E)-8-(3,4-dimetoxiestiril)-1,3-dietil-7-metilxantina, o una sal farmacéuticamente aceptable de la misma, a un paciente que lo necesita y similares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50903902P | 2002-12-27 | 2002-12-27 | |
| US33062302A | 2002-12-27 | 2002-12-27 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR056615A1 true AR056615A1 (es) | 2007-10-17 |
Family
ID=32682652
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030104811A AR056615A1 (es) | 2002-12-27 | 2003-12-23 | Un metodo de tratamiento de trastornos de la conducta |
Country Status (15)
| Country | Link |
|---|---|
| US (2) | US20060069107A1 (es) |
| EP (1) | EP1581163A2 (es) |
| JP (1) | JP2006513207A (es) |
| KR (1) | KR20050084309A (es) |
| CN (1) | CN1732005A (es) |
| AR (1) | AR056615A1 (es) |
| AU (1) | AU2003299432A1 (es) |
| BR (1) | BR0317772A (es) |
| CA (1) | CA2511779A1 (es) |
| CO (1) | CO5590922A2 (es) |
| EA (1) | EA200501052A1 (es) |
| MX (1) | MXPA05006860A (es) |
| TW (1) | TW200501958A (es) |
| WO (1) | WO2004058139A2 (es) |
| ZA (1) | ZA200504955B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1709966A4 (en) * | 2003-12-09 | 2009-04-29 | PREVENTIVE AND / OR THERAPEUTIC AGENT FOR SEVERE CEREBRAL DYSFUNCTION | |
| US9265458B2 (en) | 2012-12-04 | 2016-02-23 | Sync-Think, Inc. | Application of smooth pursuit cognitive testing paradigms to clinical drug development |
| US9380976B2 (en) | 2013-03-11 | 2016-07-05 | Sync-Think, Inc. | Optical neuroinformatics |
| JP7382737B2 (ja) * | 2019-05-13 | 2023-11-17 | 東和薬品株式会社 | イストラデフィリン製剤 |
| JP7557863B2 (ja) * | 2020-10-12 | 2024-09-30 | 共和薬品工業株式会社 | イストラデフィリン含有医薬組成物 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1016407B1 (en) * | 1997-09-05 | 2006-05-10 | Kyowa Hakko Kogyo Co., Ltd. | Xanthine derivatives for treating brain ischemia |
| CA2413086C (en) * | 2000-06-21 | 2011-06-28 | Alexander Alanine | Benzothiazole derivatives |
| CN101822676A (zh) * | 2002-01-28 | 2010-09-08 | 协和发酵麒麟株式会社 | 治疗运动疾病患者的方法 |
-
2003
- 2003-12-23 AR ARP030104811A patent/AR056615A1/es not_active Application Discontinuation
- 2003-12-24 WO PCT/IB2003/006455 patent/WO2004058139A2/en not_active Ceased
- 2003-12-24 KR KR1020057010951A patent/KR20050084309A/ko not_active Withdrawn
- 2003-12-24 AU AU2003299432A patent/AU2003299432A1/en not_active Abandoned
- 2003-12-24 MX MXPA05006860A patent/MXPA05006860A/es unknown
- 2003-12-24 BR BR0317772-6A patent/BR0317772A/pt not_active IP Right Cessation
- 2003-12-24 EA EA200501052A patent/EA200501052A1/ru unknown
- 2003-12-24 JP JP2004563530A patent/JP2006513207A/ja not_active Withdrawn
- 2003-12-24 CA CA002511779A patent/CA2511779A1/en not_active Abandoned
- 2003-12-24 EP EP03799729A patent/EP1581163A2/en not_active Withdrawn
- 2003-12-24 CN CNA2003801075170A patent/CN1732005A/zh active Pending
- 2003-12-24 US US10/539,574 patent/US20060069107A1/en not_active Abandoned
- 2003-12-26 TW TW092137061A patent/TW200501958A/zh unknown
-
2005
- 2005-06-17 ZA ZA200504955A patent/ZA200504955B/en unknown
- 2005-07-26 CO CO05073277A patent/CO5590922A2/es not_active Application Discontinuation
-
2008
- 2008-09-29 US US12/239,955 patent/US20090023755A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| KR20050084309A (ko) | 2005-08-26 |
| ZA200504955B (en) | 2006-04-26 |
| EA200501052A1 (ru) | 2005-12-29 |
| MXPA05006860A (es) | 2005-08-18 |
| WO2004058139A2 (en) | 2004-07-15 |
| CN1732005A (zh) | 2006-02-08 |
| EP1581163A2 (en) | 2005-10-05 |
| CA2511779A1 (en) | 2004-07-15 |
| US20090023755A1 (en) | 2009-01-22 |
| TW200501958A (en) | 2005-01-16 |
| AU2003299432A1 (en) | 2004-07-22 |
| US20060069107A1 (en) | 2006-03-30 |
| BR0317772A (pt) | 2005-11-22 |
| WO2004058139A3 (en) | 2004-11-04 |
| JP2006513207A (ja) | 2006-04-20 |
| CO5590922A2 (es) | 2005-12-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR026610A1 (es) | Un derivado pirrolidinacetamida solo o en combinacion para tratamiento de desordenes del sistema nervioso central | |
| AR047841A1 (es) | Metodos y composiciones para el tratamiento de transtornos inmunoinflamatorios | |
| CY1111359T1 (el) | Μεμαντινη για την θεραπεια ηπιας εως μετριας ασθενειας alzheimer | |
| MEP42808A (en) | Use of flibanserin in the treatment of sexual disorders | |
| WO2004006858A3 (en) | Compounds, compositions, and methods employing same | |
| TW200507830A (en) | Bronchodilating β -agonist compositions and methods | |
| IL225192A (en) | Combinations of dextromethorphan and quinidine for the preparation of mental illness, neuropathic pain or brain injury | |
| FR2869231B1 (fr) | Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine | |
| ATE433973T1 (de) | Azolylaminoazine als inhibitoren von proteinkinasen | |
| EA201001695A1 (ru) | Применение эпотилона d для лечения заболеваний, связанных с тау-белком | |
| WO2006076651A3 (en) | Treatment method | |
| DK1654253T3 (da) | Substituerede 3-pyrrolidinindolderivater | |
| WO2003092617A3 (en) | Combinations for the treatment of inflammatory skin disorders | |
| CY1113116T1 (el) | Υποκατεστημενες 4-αμινοκυκλοεξανολες | |
| WO2008045378A3 (en) | Treatment of infant hyperbilirubinemia using low dosages of stannsoporfin | |
| CY1110369T1 (el) | Νεος συνεργιστικος συνδυασμος ο οποιος περιεχει ροφλουμιλαστη και φορμοτερολη | |
| ES2422286T3 (es) | Uso de apamina para tratar la enfermedad de Parkinson | |
| AR056615A1 (es) | Un metodo de tratamiento de trastornos de la conducta | |
| NO990450L (no) | Behandling av sinnslidelser | |
| ATE548048T1 (de) | Oncomodulin zur behandlung von neurologishen erkrankungen | |
| ATE487485T1 (de) | Verwendung von d-ribose zur behandlung von vorhofflimmern | |
| DK1596879T3 (da) | Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis | |
| ATE502637T1 (de) | Medikamente zur prävention oder behandlung von herzversagen mit einem anticholinergikum | |
| DE602004016547D1 (de) | 1,4-dihydropyridinverbindungen, pharmazeutische verbindungen, und verfahren zur behandlung von herzkreislauferkrankungen | |
| HRP20050580B1 (hr) | Sinergistiäśki uäśinak kombinacije roflumilasta i (r,r)-formoterola |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal | ||
| FA | Abandonment or withdrawal |